Company profile
AKARI THERAPEUTICS PLC
NASDAQ:AKTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NOMACOPAN | phase3 | — | 4 | completed, terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03427060 | phase2 | completed | 2018-05-14 | 2018-11-15 | AKARI Therapeutics | Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms |
| NCT02591862 | phase2 | completed | 2016-02-01 | 2018-03-20 | AKARI Therapeutics | Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) |
| NCT04784455 | phase3 | terminated | 2021-02-01 | 2024-05-15 | AKARI Therapeutics | Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy |
| NCT05061771 | phase3 | withdrawn | 2022-05-06 | 2022-08-01 | AKARI Therapeutics | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) |
| NCT04037891 | phase1_2 | terminated | 2019-03-04 | 2020-04-30 | AKARI Therapeutics | Topical rVA576 for Treatment of Atopic Keratoconjunctivitis |
FDA applications (0)
No records yet.